hero image
Giovanni Marotta, MD - Vielight. Toronto, ON, CANADA

Giovanni Marotta, MD

Principal Investigator | Vielight

Toronto, ON, CANADA

Dr. Marotta is an expert in dementia research and palliative care

Media

Publications:

Documents:

Photos:

Videos:

Giovanni Marotta, MD Youtube Giovanni Marotta, MD Youtube

Audio/Podcasts:

Biography

Dr. Giovanni Marotta is a geriatrician in Toronto. He sees patients in the community, in hospital and in long-term care facilities. He is the clinical advisor to the CBAO Seniors Day Program, a unique pilot program now offered in Vaughan and in the Italian language for these seniors with early-stage dementia. One of only three Italian-speaking geriatricians in the city, Dr. Marotta offers a structured schedule of physical, mental and social activities through his facilitation of this program.

Industry Expertise (6)

Health Care - Services

Health Care - Facilities

Mental Health Care

Research

Health and Wellness

Health Care - Providers

Areas of Expertise (5)

Psychiatry

Dementia Disorders

Palliative Care

Gerontology Research

Memory and Cognition

Articles (5)

Risk factors in multiple sclerosis: a population-based case–control study in Sicily. Background and methods


Neurological Sciences

2016 Incidence of multiple sclerosis (MS) has steeply increased over time during the last 30 years in the city of Catania. We carried out a population-based case–control study to evaluate the possible role of both environmental and genetic factors. From 1975 to 2004 in Catania, 367 MS patients diagnosed according to the Poser’s criteria had the onset of disease. A sample of MS patients was randomly selected from this incident cohort. Three controls matched by age and sex were randomly selected from the rosters of 14 GPs. Controls were proportionally selected according to the distribution by municipality of the target population using a multistage sampling methods. All cases and controls underwent a face-to-face interview to record information concerning environmental factors and a blood sample was taken for serological and genetic analysis. 164 MS patients (64 % women; mean age of 46.4 ± 10.7) and 481 controls (69 % women; mean age of 47.7 ± 14.8) were enrolled in the study. The distribution of the whole population and the selected controls by municipalities was similar. A blood sample was taken from 150 MS cases and from 337 controls. At the end of the enrolment, we obtained a representative sample of the MS cases and population controls avoiding possible selection bias. Participation rate was very high also concerning the collection of biological specimens.

view more


Active Aβ immunotherapy cad106 phase ii dose-adjuvant finding study: safety and CNS biomarkers


Alzheimers and Dementia

2014

view more


Restless legs syndrome and multiple sclerosis: a population based case−control study in Catania, Sicily


European Journal of Neurology

2014 A population-based case−control study in the city of Catania, Sicily, was carried out to determine restless legs syndrome (RLS) prevalence and its association with multiple sclerosis (MS).

view more


Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: An active treatment extension study


Movement Disorders

2005 In patients with dementia associated with Parkinson's disease (PD), the efficacy and safety of rivastigmine, an inhibitor of acetylcholinesterase and butyrylcholinesterase, were previously demonstrated in a 24-week double-blind placebo-controlled trial. Our objective was to determine whether benefits were sustained over the long term. Following the double-blind trial, all patients were permitted to enter an active treatment extension study, during which they received rivastigmine 3–12 mg/day. Standard safety assessments were performed. Efficacy assessments included the Alzheimer's Disease Assessment Scale cognitive subscale (ADAS-cog) and other measures of cognition, daily function, neuropsychiatric symptoms, and executive function. Of 433 patients who completed the double-blind trial, 334 entered and 273 completed the active treatment extension. At 48 weeks, the mean ADAS-cog score for the whole group improved by 2 points above baseline. Placebo patients switching to rivastigmine for the active treatment extension experienced a mean cognitive improvement similar to that of the original rivastigmine group during the double-blind trial. The adverse event profile was comparable to that seen in the double-blind trial. Long-term rivastigmine treatment appeared well tolerated and may provide sustained benefits in dementia associated with PD patients who remain on treatment for up to 48 weeks.

view more


Preparation of Bicyclo[3.2.0]heptane-2-endo,7-endo-diols:  1,3-Diols with a Chiral Rigid Backbone


Journal of Organic Chemistry

2004 The easily available bicyclo[3.2.0]hept-3-en-6-ones (1a−f) have been converted into the corresponding bicyclo[3.2.0]heptane-2-endo,7-endo-diols (4a−f) in an efficient and stereoselective fashion. This preparation opens a route to a family of 1,3-diols with a chiral rigid backbone, potentially suitable as nonracemic precursors for bidentate ligands in asymmetric synthesis.

view more


 Your profile is not published.

Contact